Neoadjuvant GOLP therapy significantly enhances event-free survival in patients with resectable high-risk intrahepatic cholangiocarcinoma.

• Median event-free survival was 18.0 months with GOLP, compared to 8.7 months in the control group (p<0.001).
• Overall survival at 24 months was 79% for the neoadjuvant group vs. 61% for controls (hazard ratio 0.43).

Expect lower-grade adverse events overall, with 97% experiencing any adverse event in the neoadjuvant group.

• Grade 3 or higher adverse events occurred in 28% of patients during neoadjuvant treatment, without treatment-related deaths.

Medicaid expansion improves survival and surgical access for pancreatic cancer patients.

• Residents in states with early, on-time, and late Medicaid expansion had 2-year mortality reductions (hazard ratios ranging from 0.91 to 0.94).
• There was a 19% increase in the odds of surgical resection with Medicaid expansion (odds ratio 1.19).

Outcomes improved primarily after three years post-expansion, highlighting the need for equitable access initiatives, especially for lower-income patients.

• Geographic disparities in survival decreased, but income-related disparities persisted.

Transplanting liver patients who respond to atezolizumab-bevacizumab is promising for those with intermediate and advanced hepatocellular carcinoma.

• Recurrence-free survival is 90% and overall survival is 94% at two years post-transplant.
• Acute rejection rates are 25%, but remain manageable; 62.5% had complications within 90 days of transplant.

Surgical teams should consider immunotherapy response when selecting candidates for liver transplantation in advanced HCC.